Table 1.
Behavioural and clinical characteristics of the women in this study
| Characteristic | All (N=48) | Tenofovir (N=24) | Placebo (N=24) |
|---|---|---|---|
| Rural % (n) | 58.3% (28) | 58.3% (14) | 58.3% (14) |
| Median Age in years (IQR) | 23 (22-25) | 24 (22-28) | 22 (22-23) |
| Median days PI* at enrolment (IQR) | 38 (24-65) | 35 (27-63) | 45 (23-65) |
| Median CD4 count (cells/μl) (IQR) | 498 (434-655) | 468 (444-569) | 515 (433-685) |
| Median viral load (copies/ml) (IQR) | 59050 (17300-135500) | 80600 (22000-130000) | 54800 (13600-148000) |
| Time to HIV-infection from enrolment in months (IQR)◆ | 9.2 (4.9-14.1) | 12.8 (6.6-16.6) | 7.4 (3.3-10.6) |
| Completed high school % (n) | 54.2% (26) | 41.7% (10) | 66.7% (16) |
| Hormonal contraception# (n) | 97.9% (47) | 100% (24) | 95.8% (23) |
| Marital status % (n) | |||
| Stable/married partner | 79.2% (38) | 87.5% (21) | 70.8% (17) |
| > 2 partners | 2.1% (1) | 0.0% (0) | 4.2% (1) |
| Single | 18.7% (9) | 12.5% (3) | 25.0% (6) |
| Number of reported sexual partners in the last 3 months** % (n) | |||
| 0 to 1 | 93.8% (45) | 95.8% (23) | 91.7% (22) |
| 2 to 5 | 6.2% (3) | 4.2% (1) | 8.3% (2) |
| Reported condom used at last sex act % (n) | 68.8% (33) | 75.0% (18) | 62.5% (15) |
*
PI = post-infection
**
Two non-rapid progressing women had missing sexual partner data (in previous 3 months) as they refused to answer the question.
#
Hormonal contraception use included the injectable depot medroxyprogesterone acetate and norethisterone, and oral combined contraception. One woman in the placebo arm of the study was using an intrauterine device.
◆
Time to HIV infection was significantly different between the tenofovir and placebo arms- p= 0.02.